Riskpilot← Back to searchSign inGet full accessBioPhero ApS
APSDissolvedCVR 38109340Lersø Parkallé 42, 4.Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 201628 employees
Revenue 2022
DKK -3,6M
+124% vs 2021
EBITDA margin
561.0%
-48% vs 2021
Equity ratio
94.6%
Financial strength
Net profit 2022
DKK -17,4M
-19% vs 2021
| Revenue | DKK -3,6M | +124% |
| EBITDA | DKK -20,1M | -48% |
| Net profit | DKK -17,4M | -19% |
| Total assets | DKK 90M | +28% |
| Equity | DKK 85,1M | +28% |
| Employees | 28 | — |
Legal name
BioPhero ApS
CVR number
38109340
Legal form
Anpartsselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
4. oktober 2016
Share capital
DKK 309.290
Employees
28 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af formanden for bestyrelsen, eller af et medlem af direktionen i forening med et bestyrelsesmedlem, eller af den samlede bestyrelse.
Address
Lersø Parkallé 42, 4.
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 1.623 | 1.655 | 5.136 | -1.600 | -3.590 |
| Staff expenses | -0 | -1.522 | -5.820 | -8.569 | -12.003 | -16.547 |
| EBITDA | -7 | 101 | -4.164 | -3.433 | -13.603 | -20.137 |
| Depreciation & amort. | -0 | -101 | -502 | -660 | -1.370 | -1.832 |
| EBIT | -7 | 0 | -4.666 | -4.094 | -14.973 | -21.968 |
| Net financials | 0 | -0 | -55 | -70 | 306 | -141 |
| Profit before tax | -7 | 0 | -4.722 | -4.164 | -14.667 | -22.109 |
| Tax | -0 | -0 | -0 | -1.116 | -0 | -4.708 |
| Net profit | -7 | 0 | -4.722 | -3.048 | -14.667 | -17.402 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Total assets | 43 | 8.422 | 12.873 | 27.745 | 70.274 | 89.985 |
| Equity | 43 | 3.848 | 10.301 | 14.703 | 66.697 | 85.099 |
| Long-term debt | 0 | 0 | 0 | 0 | 761 | 709 |
| Short-term debt | 0 | 4.574 | 2.572 | 13.041 | 2.817 | 4.177 |
| Total debt | 0 | 4.574 | 2.572 | 13.041 | 3.577 | 4.886 |
EBITDA margin
-2013675200.0%
This company
15.8%
Market median
-12744779847% vs market
20172022
Equity ratio
94.6%
This company
38.2%
Market median
+148% vs market
20172022
Return on equity
-20.4%
This company
18.4%
Market median
-211% vs market
20172022
Net profit margin
-1740151700.0%
This company
8.1%
Market median
-21483354421% vs market
20172022
Asset turnover
-0.04×
This company
1.12×
Market median
-104% vs market
20172022
Debt / equity
0.06×
This company
0.62×
Market median
+90% vs market
20172022
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-04 – 2017-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KB Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
MG Management | Management | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 20.0% | 0.0% | 2018 | |
Novo Holdings A/S | Company | 20.0% | 20.0% | 2022 |
| Individual | 15.0% | 15.0% | 2022 | |
| Individual | 5.0% | 5.0% | 2022 | |
Uddannelses- og Forskningsstyrelsen | Company | 5.0% | 5.0% | 2019 |
Phero Holding ApS | Company | 15.0% | 15.0% | 2021 |
CHEMINOVA A/S | Company | 100.0% | 100.0% | 2022 |
| Individual | 100.0% | 100.0% | 2017 | |
BioCH ApS | Company | 5.0% | 5.0% | 2018 |
| Individual | 33.3% | 33.3% | 2022 | |
| Individual | 15.0% | 15.0% | 2018 | |
| Individual | 15.0% | 15.0% | 2017 | |
Lentge Andersen Holding ApS | Company | 33.3% | 33.3% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BioPhero ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristian Bitsch Ebbensgaard | Chief Executive Officer | 0 companies |
| Michael Gronemann Andersen | Management | 0 companies |
| Henrik Meyer | Board of Directors | 0 companies |
| Thomas Grotkjær | Board of Directors | 0 companies |
| John Hamer | Board of Directors | 0 companies |
| Benedicte Francoise Simone Flambard | Chairman | 0 companies |
| Hadyn St Pierre Parry | Chairman | 0 companies |
| Michael James Lee | Board of Directors | 0 companies |
| Helge Holm-Larsen | Board of Directors | 0 companies |
| William Francis Chester | Board of Directors | 0 companies |
| Peter Smedegaard | Chairman | 0 companies |
| Jakob Lyngsø Andersen | Board of Directors | 0 companies |